Sava Infond d.o.o. Buys New Holdings in Eli Lilly and Company (NYSE:LLY)

Sava Infond d.o.o. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 9,610 shares of the company’s stock, valued at approximately $7,419,000. Eli Lilly and Company comprises 1.3% of Sava Infond d.o.o.’s holdings, making the stock its 17th biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares in the last quarter. Penserra Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 45.2% during the third quarter. Penserra Capital Management LLC now owns 870 shares of the company’s stock worth $770,000 after purchasing an additional 271 shares in the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Eli Lilly and Company by 24.7% in the third quarter. Loomis Sayles & Co. L P now owns 1,869 shares of the company’s stock worth $1,656,000 after buying an additional 370 shares during the period. Quantbot Technologies LP grew its stake in shares of Eli Lilly and Company by 115.3% in the third quarter. Quantbot Technologies LP now owns 3,757 shares of the company’s stock valued at $3,328,000 after buying an additional 2,012 shares in the last quarter. Finally, Baldwin Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 2.4% during the 3rd quarter. Baldwin Investment Management LLC now owns 8,354 shares of the company’s stock valued at $7,401,000 after buying an additional 195 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Citigroup cut their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

Eli Lilly and Company Price Performance

Shares of LLY opened at $826.84 on Thursday. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The stock’s fifty day moving average is $841.16 and its 200-day moving average is $837.54. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market capitalization of $783.98 billion, a price-to-earnings ratio of 70.61, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.